HDAC2 and mature T-cell and NK-cell non-Hodgkin lymphoma: In the cyclic peptide group, romidepsin, also named FK228 or depsipeptide, inhibits HDAC1 and HDAC2 and was the second HDAC inhibitor approved by the U.S. FDA to treat CTCL and PTCL.